Protocol Ledger

NCT05115942 · Phase III · COMPLETED

Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Interventional Phase III clinical trial protocol NCT05115942 sponsored by Beijing Continent Pharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-30 Enrollment: 248 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05115942
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)248 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05115942
Protocol FieldVerified Registry Value
NCT IdentifierNCT05115942
Consolidated Lead SponsorBeijing Continent Pharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment248 participants (ACTUAL)
Registered Start Date2021-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI